Company profile: Cygnus Technologies
1.1 - Company Overview
Company description
- Provider of generic kits, immunoassay reagents, and antibody and assay development services to pharmaceutical and biotechnology industries. Specializes in custom antibody and assay development for host cell protein detection in recombinant pharmaceuticals and supplies specialized analytical products.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cygnus Technologies
NAT Diagnostics
HQ: United States
Website
- Description: Provider of a molecular diagnostic platform for true point-of-care infectious disease testing in physician offices, clinics, pharmacies, and other sites where patients are seen by medical personnel, delivering highly accurate results to improve the diagnostic experience.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NAT Diagnostics company profile →
Fulcrum Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology therapies targeting rare genetic diseases at their root cause, including losmapimod (a small molecule under investigation for facioscapulohumeral muscular dystrophy) and FTX-6058 (a small molecule designed to increase expression of fetal hemoglobin for treating sickle cell disease and beta-thalassemia).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fulcrum Therapeutics company profile →
RealTime Laboratories
HQ: United States
Website
- Description: Provider of the only U.S. CAP- and CLIA-accredited clinical mycotoxin testing, with comprehensive panels for indoor mold-related mycotoxins; at-home specimen collection kits; complimentary physician and patient navigator consultations to explain results; environmental pollutant profile testing; and glyphosate exposure analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RealTime Laboratories company profile →
Lexicon Pharmaceuticals
HQ: United States
Website
- Description: Provider of precise medicines for human disease, including INPEFA (sotagliflozin), a once-daily oral tablet that reduces the risk of cardiovascular death, heart failure hospitalization and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. Pipeline includes LX9211 for DPNP (AAK1) and sotagliflozin for type 1 diabetes (US regulatory) and HCM (preclinical).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lexicon Pharmaceuticals company profile →
Arrakis Therapeutics
HQ: United States
Website
- Description: Provider of RNA-targeted drug discovery tools and small-molecule therapeutics, including the rSM Toolkit to identify RNA substructures, Direct Modulators that bind RNA, Targeted RNA Degraders, and Covalent Modifiers that block translation. Maintains pipeline programs for cancer, cardiovascular conditions, neurodegeneration, and rare diseases, including an rSM program for DM1.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arrakis Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cygnus Technologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cygnus Technologies
2.2 - Growth funds investing in similar companies to Cygnus Technologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cygnus Technologies
4.2 - Public trading comparable groups for Cygnus Technologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →